A Hypothesis-Generating Pharmacologic Profile for Sargramostim Treatment of Parkinson's Disease.

Cell Mol Neurobiol · 2026 · PMC13172246 · PMID 41920366

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.4964

boldest claim

The sentences

marginally significantp = 0.080so close (0.05 < p ≤ 0.1)

The association was marginally significant ( p = 0.080) indicating a potential relationship with a 95% confidence interval for β1 of [−7.86, 0.61].

also in 26,082 other papers

an increasing trendp = 0.4964not close (p > 0.1)

Male patients showed an increasing trend with mean δ UPDRS scores of 1.66 at 6 months ( p = 0.4964, Z = 1.155) of treatment and 4.40 by 12 months ( p = 0.2978, Z = 1.443) (Fig. 5 A-B), while female patients demonstrated means of 1.25 at 6 months ( p > 0.9999, Z = 0.3536) and a significant increase ( p = 0.0431, Z = 2.298) to 7.75 at 12 months (Fig. 5 E-F).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.